APA (7th ed.) Citation

R, B., L, S. G., L, K., EL, S., LF, E., J, B., . . . JI, S. (2025). Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. Journal of the American Academy of Dermatology, 93(3), 707. https://doi.org/10.1016/j.jaad.2025.05.1391

Chicago Style (17th ed.) Citation

R, Bissonnette, et al. "Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis." Journal of the American Academy of Dermatology 93, no. 3 (2025): 707. https://doi.org/10.1016/j.jaad.2025.05.1391.

MLA (9th ed.) Citation

R, Bissonnette, et al. "Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis." Journal of the American Academy of Dermatology, vol. 93, no. 3, 2025, p. 707, https://doi.org/10.1016/j.jaad.2025.05.1391.